CA2900668A1 - Treatment of melanoma with nanoparticles comprising paclitaxel - Google Patents
Treatment of melanoma with nanoparticles comprising paclitaxel Download PDFInfo
- Publication number
- CA2900668A1 CA2900668A1 CA2900668A CA2900668A CA2900668A1 CA 2900668 A1 CA2900668 A1 CA 2900668A1 CA 2900668 A CA2900668 A CA 2900668A CA 2900668 A CA2900668 A CA 2900668A CA 2900668 A1 CA2900668 A1 CA 2900668A1
- Authority
- CA
- Canada
- Prior art keywords
- individual
- melanoma
- paclitaxel
- braf
- albumin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 646
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 445
- 238000011282 treatment Methods 0.000 title claims abstract description 100
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims description 641
- 229960001592 paclitaxel Drugs 0.000 title claims description 612
- 229930012538 Paclitaxel Natural products 0.000 title claims description 352
- 239000000203 mixture Substances 0.000 claims abstract description 389
- 238000000034 method Methods 0.000 claims abstract description 362
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 387
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 386
- 102000009027 Albumins Human genes 0.000 claims description 300
- 108010088751 Albumins Proteins 0.000 claims description 300
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims description 259
- 208000021039 metastatic melanoma Diseases 0.000 claims description 259
- 241000282414 Homo sapiens Species 0.000 claims description 241
- 230000035772 mutation Effects 0.000 claims description 177
- 210000002966 serum Anatomy 0.000 claims description 129
- 102200055464 rs113488022 Human genes 0.000 claims description 86
- 230000003442 weekly effect Effects 0.000 claims description 52
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 34
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 34
- 239000003814 drug Substances 0.000 claims description 33
- 229960005386 ipilimumab Drugs 0.000 claims description 26
- 229940124597 therapeutic agent Drugs 0.000 claims description 26
- 238000002560 therapeutic procedure Methods 0.000 claims description 21
- 229940125431 BRAF inhibitor Drugs 0.000 claims description 15
- 238000009093 first-line therapy Methods 0.000 claims description 7
- 238000009094 second-line therapy Methods 0.000 claims description 6
- 229940123237 Taxane Drugs 0.000 abstract description 144
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract description 144
- 102000014914 Carrier Proteins Human genes 0.000 abstract description 105
- 108010078791 Carrier Proteins Proteins 0.000 abstract description 105
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 description 259
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 200
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 200
- -1 albumin) Chemical class 0.000 description 158
- 230000001394 metastastic effect Effects 0.000 description 136
- 206010061289 metastatic neoplasm Diseases 0.000 description 135
- 230000000694 effects Effects 0.000 description 130
- 208000030381 cutaneous melanoma Diseases 0.000 description 99
- 201000003708 skin melanoma Diseases 0.000 description 97
- 238000002512 chemotherapy Methods 0.000 description 49
- 108091000080 Phosphotransferase Proteins 0.000 description 44
- 102000020233 phosphotransferase Human genes 0.000 description 44
- 239000002246 antineoplastic agent Substances 0.000 description 41
- 229940127089 cytotoxic agent Drugs 0.000 description 41
- 229960000397 bevacizumab Drugs 0.000 description 36
- 206010028980 Neoplasm Diseases 0.000 description 34
- 108010012934 Albumin-Bound Paclitaxel Proteins 0.000 description 30
- 206010027476 Metastases Diseases 0.000 description 30
- 229940028652 abraxane Drugs 0.000 description 30
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 27
- 229960004964 temozolomide Drugs 0.000 description 23
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 22
- 229960004562 carboplatin Drugs 0.000 description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 229960000435 oblimersen Drugs 0.000 description 21
- MIMNFCVQODTQDP-NDLVEFNKSA-N oblimersen Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(S)(=O)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP(O)(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(NC(=O)C(C)=C2)=O)CO)[C@@H](O)C1 MIMNFCVQODTQDP-NDLVEFNKSA-N 0.000 description 21
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 238000009097 single-agent therapy Methods 0.000 description 20
- 239000002955 immunomodulating agent Substances 0.000 description 19
- 231100000433 cytotoxic Toxicity 0.000 description 17
- 230000001472 cytotoxic effect Effects 0.000 description 17
- 239000002245 particle Substances 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- 229960003901 dacarbazine Drugs 0.000 description 16
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 description 16
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 14
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 14
- 201000005969 Uveal melanoma Diseases 0.000 description 14
- 102000014150 Interferons Human genes 0.000 description 13
- 108010050904 Interferons Proteins 0.000 description 13
- 238000001802 infusion Methods 0.000 description 13
- 229940079322 interferon Drugs 0.000 description 13
- 201000011510 cancer Diseases 0.000 description 12
- 206010061818 Disease progression Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 230000005750 disease progression Effects 0.000 description 11
- 229960003787 sorafenib Drugs 0.000 description 11
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 208000025865 Ulcer Diseases 0.000 description 9
- 230000009401 metastasis Effects 0.000 description 9
- 230000004044 response Effects 0.000 description 9
- 230000036269 ulceration Effects 0.000 description 9
- 229960003862 vemurafenib Drugs 0.000 description 9
- 102100039788 GTPase NRas Human genes 0.000 description 8
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 8
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 8
- 238000011393 cytotoxic chemotherapy Methods 0.000 description 8
- 230000002440 hepatic effect Effects 0.000 description 8
- 238000009169 immunotherapy Methods 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 8
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical group [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 8
- 208000037992 stage IV cutaneous melanoma Diseases 0.000 description 8
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 description 8
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 229940034727 zelboraf Drugs 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 231100000402 unacceptable toxicity Toxicity 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 5
- 229960002465 dabrafenib Drugs 0.000 description 5
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000003902 lesion Effects 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 229910052697 platinum Inorganic materials 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960004066 trametinib Drugs 0.000 description 4
- 238000011277 treatment modality Methods 0.000 description 4
- DKNUPRMJNUQNHR-UHFFFAOYSA-N 1-[3-(6,7-dimethoxyquinazolin-4-yl)oxyphenyl]-3-[5-(1,1,1-trifluoro-2-methylpropan-2-yl)-1,2-oxazol-3-yl]urea Chemical compound C=12C=C(OC)C(OC)=CC2=NC=NC=1OC(C=1)=CC=CC=1NC(=O)NC=1C=C(C(C)(C)C(F)(F)F)ON=1 DKNUPRMJNUQNHR-UHFFFAOYSA-N 0.000 description 3
- YTDHTKGXXMJUSH-UHFFFAOYSA-N 1-[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[2-methylsulfanyl-4-[(3-oxo-4h-pyrido[2,3-b]pyrazin-8-yl)oxy]phenyl]urea Chemical compound CSC1=CC(OC=2C=3N=CC(=O)NC=3N=CC=2)=CC=C1NC(=O)NC1=CC(C(C)(C)C)=NN1C1=CC=C(C)C=C1 YTDHTKGXXMJUSH-UHFFFAOYSA-N 0.000 description 3
- YABJJWZLRMPFSI-UHFFFAOYSA-N 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-2-benzimidazolamine Chemical compound N=1C2=CC(OC=3C=C(N=CC=3)C=3NC(=CN=3)C(F)(F)F)=CC=C2N(C)C=1NC1=CC=C(C(F)(F)F)C=C1 YABJJWZLRMPFSI-UHFFFAOYSA-N 0.000 description 3
- NMIZONYLXCOHEF-UHFFFAOYSA-N 1h-imidazole-2-carboxamide Chemical compound NC(=O)C1=NC=CN1 NMIZONYLXCOHEF-UHFFFAOYSA-N 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 3
- DEZZLWQELQORIU-RELWKKBWSA-N GDC-0879 Chemical compound N=1N(CCO)C=C(C=2C=C3CCC(/C3=CC=2)=N\O)C=1C1=CC=NC=C1 DEZZLWQELQORIU-RELWKKBWSA-N 0.000 description 3
- 229940124647 MEK inhibitor Drugs 0.000 description 3
- 206010059282 Metastases to central nervous system Diseases 0.000 description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 3
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 3
- YZDJQTHVDDOVHR-UHFFFAOYSA-N PLX-4720 Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(Cl)=CN=C3NC=2)=C1F YZDJQTHVDDOVHR-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007954 hypoxia Effects 0.000 description 3
- CMJCXYNUCSMDBY-ZDUSSCGKSA-N lgx818 Chemical compound COC(=O)N[C@@H](C)CNC1=NC=CC(C=2C(=NN(C=2)C(C)C)C=2C(=C(NS(C)(=O)=O)C=C(Cl)C=2)F)=N1 CMJCXYNUCSMDBY-ZDUSSCGKSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 3
- 201000003731 mucosal melanoma Diseases 0.000 description 3
- ACIXGVIVJZJKNT-UHFFFAOYSA-N n-[2,4-difluoro-3-[[3-(7h-purin-6-yl)pyridin-2-yl]amino]phenyl]furan-3-sulfonamide Chemical compound FC1=C(NC=2C(=CC=CN=2)C=2C=3N=CNC=3N=CN=2)C(F)=CC=C1NS(=O)(=O)C=1C=COC=1 ACIXGVIVJZJKNT-UHFFFAOYSA-N 0.000 description 3
- 229940080607 nexavar Drugs 0.000 description 3
- 201000000032 nodular malignant melanoma Diseases 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- FNHKPVJBJVTLMP-UHFFFAOYSA-N regorafenib Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=C(F)C(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 FNHKPVJBJVTLMP-UHFFFAOYSA-N 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 229960000487 sorafenib tosylate Drugs 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000009095 third-line therapy Methods 0.000 description 3
- 230000009278 visceral effect Effects 0.000 description 3
- 229940055760 yervoy Drugs 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 2
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 2
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 206010024218 Lentigo maligna Diseases 0.000 description 2
- 206010027458 Metastases to lung Diseases 0.000 description 2
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 2
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 2
- 206010029488 Nodular melanoma Diseases 0.000 description 2
- 108091007744 Programmed cell death receptors Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 206010000583 acral lentiginous melanoma Diseases 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000001146 hypoxic effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000011080 lentigo maligna melanoma Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 201000002575 ocular melanoma Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 208000030457 superficial spreading melanoma Diseases 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- YZEUHQHUFTYLPH-UHFFFAOYSA-N 2-nitroimidazole Chemical group [O-][N+](=O)C1=NC=CN1 YZEUHQHUFTYLPH-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 description 1
- 229940126161 DNA alkylating agent Drugs 0.000 description 1
- 239000012624 DNA alkylating agent Substances 0.000 description 1
- 206010072449 Desmoplastic melanoma Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000002633 Febrile Neutropenia Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 206010073086 Iris melanoma Diseases 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 101710183263 Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- NBZAOYGRIPZYPC-UHFFFAOYSA-N aminophosphonic acid;2-nitro-1h-imidazole Chemical compound NP(O)(O)=O.[O-][N+](=O)C1=NC=CN1 NBZAOYGRIPZYPC-UHFFFAOYSA-N 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 239000003817 anthracycline antibiotic agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 101150048834 braF gene Proteins 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 238000009110 definitive therapy Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000002767 hepatic artery Anatomy 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000005414 inactive ingredient Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000009092 lines of therapy Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 201000002350 malignant ciliary body melanoma Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000010309 neoplastic transformation Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 208000016450 non-cutaneous melanoma Diseases 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 239000012663 orally bioavailable inhibitor Substances 0.000 description 1
- 229940044205 orally bioavailable inhibitor Drugs 0.000 description 1
- 229960002502 paclitaxel protein-bound Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 201000002267 posterior uveal melanoma Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 210000005005 sentinel lymph node Anatomy 0.000 description 1
- 238000011270 sentinel node biopsy Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000004222 uncontrolled growth Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Oncology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361763391P | 2013-02-11 | 2013-02-11 | |
| US61/763,391 | 2013-02-11 | ||
| US13/791,841 US9149455B2 (en) | 2012-11-09 | 2013-03-08 | Methods of treating melanoma |
| US13/791,841 | 2013-03-08 | ||
| PCT/US2013/072877 WO2014123612A1 (en) | 2013-02-11 | 2013-12-03 | Methods of treating melanoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2900668A1 true CA2900668A1 (en) | 2014-08-14 |
Family
ID=51300036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2900668A Abandoned CA2900668A1 (en) | 2013-02-11 | 2013-12-03 | Treatment of melanoma with nanoparticles comprising paclitaxel |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2953622B1 (enExample) |
| JP (3) | JP6388880B2 (enExample) |
| KR (1) | KR102148551B1 (enExample) |
| CN (2) | CN105120859B (enExample) |
| BR (1) | BR112015019064A8 (enExample) |
| CA (1) | CA2900668A1 (enExample) |
| ES (1) | ES2872328T3 (enExample) |
| HK (1) | HK1218506A1 (enExample) |
| IL (1) | IL240388B (enExample) |
| MX (1) | MX377729B (enExample) |
| NZ (1) | NZ630239A (enExample) |
| WO (1) | WO2014123612A1 (enExample) |
| ZA (1) | ZA201505956B (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR101894689B1 (ko) | 2010-03-29 | 2018-09-04 | 아브락시스 바이오사이언스, 엘엘씨 | 암의 치료 방법 |
| WO2012154861A2 (en) | 2011-05-09 | 2012-11-15 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| EP2903610B1 (en) | 2012-10-01 | 2021-11-03 | Mayo Foundation For Medical Education And Research | Cancer treatments |
| US9149455B2 (en) | 2012-11-09 | 2015-10-06 | Abraxis Bioscience, Llc | Methods of treating melanoma |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| WO2015095842A2 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers |
| WO2015195476A1 (en) | 2014-06-16 | 2015-12-23 | Mayo Foundation For Medical Education And Research | Treating myelomas |
| US9446148B2 (en) | 2014-10-06 | 2016-09-20 | Mayo Foundation For Medical Education And Research | Carrier-antibody compositions and methods of making and using the same |
| ES2763318T3 (es) * | 2014-10-06 | 2020-05-28 | Mayo Found Medical Education & Res | Composiciones de vehículo-anticuerpo y procedimientos para preparar y usar las mismas |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| TW201707725A (zh) | 2015-08-18 | 2017-03-01 | 美國馬友醫藥教育研究基金會 | 載體－抗體組合物及其製造及使用方法 |
| WO2017031368A1 (en) * | 2015-08-18 | 2017-02-23 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| TW201713360A (en) | 2015-10-06 | 2017-04-16 | Mayo Foundation | Methods of treating cancer using compositions of antibodies and carrier proteins |
| US11571469B2 (en) | 2016-01-07 | 2023-02-07 | Mayo Foundation For Medical Education And Research | Methods of treating cancer with interferon wherein the cancer cells are HLA negative or have reduced HLA expression |
| EP3413874A4 (en) | 2016-02-12 | 2020-01-22 | Mayo Foundation for Medical Education and Research | TREATMENTS FOR BLOOD CANCER |
| EP3432928A4 (en) | 2016-03-21 | 2019-11-20 | Mayo Foundation for Medical Education and Research | PROCESS FOR IMPROVING THE THERAPEUTIC INDEX FOR CHEMOTHERAPEUTIC |
| AU2017238119A1 (en) | 2016-03-21 | 2018-10-11 | Mayo Foundation For Medical Education And Research | Methods for reducing toxicity of a chemotherapeutic drug |
| US10618969B2 (en) | 2016-04-06 | 2020-04-14 | Mayo Foundation For Medical Education And Research | Carrier-binding agent compositions and methods of making and using the same |
| MX2019002474A (es) * | 2016-09-01 | 2019-09-18 | Mayo Found Medical Education & Res | Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres. |
| JP2019526579A (ja) | 2016-09-01 | 2019-09-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ | Ｔ細胞癌を標的とする為の方法及び組成物 |
| RU2019110071A (ru) | 2016-09-06 | 2020-10-08 | Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч | Способы лечения злокачественных новообразований, экспрессирующих pd-l1 |
| CN109890422A (zh) | 2016-09-06 | 2019-06-14 | 梅约医学教育与研究基金会 | 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法 |
| WO2018048815A1 (en) | 2016-09-06 | 2018-03-15 | Nantibodyfc, Llc | Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins |
| WO2019070850A1 (en) | 2017-10-03 | 2019-04-11 | Crititech, Inc. | LOCAL ADMINISTRATION OF ANINEOPLASTIC PARTICLES IN COMBINATION WITH SYSTEMIC DELIVERY OF IMMUNOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER |
| EP3768268A4 (en) | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US6537579B1 (en) | 1993-02-22 | 2003-03-25 | American Bioscience, Inc. | Compositions and methods for administration of pharmacologically active compounds |
| US6749868B1 (en) | 1993-02-22 | 2004-06-15 | American Bioscience, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| DK1585548T3 (en) | 2002-12-09 | 2018-09-03 | Abraxis Bioscience Llc | COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS |
| US8735394B2 (en) * | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US20070166388A1 (en) * | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
| SG166775A1 (en) | 2005-02-18 | 2010-12-29 | Abraxis Bioscience Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8034765B2 (en) | 2005-08-31 | 2011-10-11 | Abraxis Bioscience, Llc | Compositions and methods for preparation of poorly water soluble drugs with increased stability |
| JP2009538317A (ja) * | 2006-05-26 | 2009-11-05 | バイエル ヘルスケア リミティド ライアビリティ カンパニー | 癌治療のための置換ジアリールウレアを用いた薬物の組み合わせ |
| US20100166869A1 (en) | 2007-05-03 | 2010-07-01 | Desai Neil P | Methods and compositions for treating pulmonary hypertension |
| EP2367425B1 (en) * | 2008-12-11 | 2018-02-28 | Abraxis BioScience, LLC | Combination therapy including a taxane and a further therapeutic agent |
| WO2012048223A1 (en) * | 2010-10-08 | 2012-04-12 | Abraxis Bioscience, Llc | Sparc microenvironment signature, plasma sparc, and ldh as prognostic biomarkers in the treatment of cancer |
-
2013
- 2013-12-03 EP EP13874757.1A patent/EP2953622B1/en active Active
- 2013-12-03 ES ES13874757T patent/ES2872328T3/es active Active
- 2013-12-03 BR BR112015019064A patent/BR112015019064A8/pt not_active Application Discontinuation
- 2013-12-03 CN CN201380075292.9A patent/CN105120859B/zh active Active
- 2013-12-03 MX MX2015010312A patent/MX377729B/es active IP Right Grant
- 2013-12-03 WO PCT/US2013/072877 patent/WO2014123612A1/en not_active Ceased
- 2013-12-03 JP JP2015556938A patent/JP6388880B2/ja active Active
- 2013-12-03 KR KR1020157024822A patent/KR102148551B1/ko active Active
- 2013-12-03 CA CA2900668A patent/CA2900668A1/en not_active Abandoned
- 2013-12-03 NZ NZ630239A patent/NZ630239A/en unknown
- 2013-12-03 HK HK16106468.2A patent/HK1218506A1/zh unknown
- 2013-12-03 CN CN201811025229.5A patent/CN109200031A/zh active Pending
-
2015
- 2015-08-06 IL IL240388A patent/IL240388B/en active IP Right Grant
- 2015-08-18 ZA ZA2015/05956A patent/ZA201505956B/en unknown
-
2017
- 2017-11-07 JP JP2017214523A patent/JP6470381B2/ja active Active
-
2019
- 2019-01-17 JP JP2019006038A patent/JP2019056014A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IL240388B (en) | 2020-07-30 |
| IL240388A0 (en) | 2015-09-24 |
| HK1218506A1 (zh) | 2017-02-24 |
| MX377729B (es) | 2025-03-11 |
| CN105120859A (zh) | 2015-12-02 |
| MX2015010312A (es) | 2015-11-18 |
| EP2953622A4 (en) | 2016-09-21 |
| CN105120859B (zh) | 2018-10-09 |
| JP2016513097A (ja) | 2016-05-12 |
| BR112015019064A8 (pt) | 2019-11-12 |
| EP2953622A1 (en) | 2015-12-16 |
| CN109200031A (zh) | 2019-01-15 |
| JP6470381B2 (ja) | 2019-02-13 |
| ES2872328T3 (es) | 2021-11-02 |
| KR102148551B1 (ko) | 2020-08-26 |
| ZA201505956B (en) | 2016-11-30 |
| EP2953622B1 (en) | 2021-03-24 |
| JP2019056014A (ja) | 2019-04-11 |
| JP6388880B2 (ja) | 2018-09-12 |
| NZ630239A (en) | 2017-08-25 |
| WO2014123612A1 (en) | 2014-08-14 |
| JP2018016660A (ja) | 2018-02-01 |
| BR112015019064A2 (pt) | 2017-07-18 |
| KR20150119177A (ko) | 2015-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018201814B2 (en) | Methods of treating melanoma | |
| EP2953622B1 (en) | Methods of treating melanoma | |
| US10328031B2 (en) | Methods of treating pancreatic cancer | |
| EP2575804A1 (en) | Methods of treatment of pancreatic cancer | |
| HK40009403A (en) | Methods of treating pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20181113 |
|
| FZDE | Discontinued |
Effective date: 20211207 |